To molecularly confirm that our new BL tumor cell lines maintained key features of eBL patient tumors, they were characterized based on the expression of B-cell lineage markers (CD20, CD10, and CD19) and for the presence of IGH or IGL/MYC translocations and EBV. The gene discussed is CD19; the disease is neoplasm.